These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18193153)

  • 1. Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays.
    Perez-Costas E; Guidetti P; Melendez-Ferro M; Kelley JJ; Roberts RC
    J Neural Transm (Vienna); 2008 May; 115(5):745-53. PubMed ID: 18193153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
    Olsen CK; Brennum LT; Kreilgaard M
    Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haloperidol both prevents and reverses quinpirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia.
    Amato D; Stasi MA; Borsini F; Nencini P
    Psychopharmacology (Berl); 2008 Oct; 200(2):157-65. PubMed ID: 18597076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat.
    Naiker DV; Catts SV; Catts VS; Bedi KS; Bryan-Lluka LJ
    Eur J Pharmacol; 2006 Jul; 540(1-3):87-90. PubMed ID: 16730699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy.
    Kapur S; VanderSpek SC; Brownlee BA; Nobrega JN
    J Pharmacol Exp Ther; 2003 May; 305(2):625-31. PubMed ID: 12606608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
    Zipursky RB; Christensen BK; Daskalakis Z; Epstein I; Roy P; Furimsky I; Sanger T; Kapur S
    Can J Psychiatry; 2005 Jul; 50(8):462-9. PubMed ID: 16127964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride.
    Mukherjee J; Christian BT; Narayanan TK; Shi B; Mantil J
    Neuropsychopharmacology; 2001 Oct; 25(4):476-88. PubMed ID: 11557161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
    Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.
    Markianos M; Hatzimanolis J; Lykouras L; Christodoulou GN
    Schizophr Res; 2002 Jul; 56(1-2):11-7. PubMed ID: 12084414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
    Markianos M; Hatzimanolis J; Lykouras L
    Eur Arch Psychiatry Clin Neurosci; 2001 Jun; 251(3):141-6. PubMed ID: 11697576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy.
    Crocker AD; Hemsley KM
    Prog Neuropsychopharmacol Biol Psychiatry; 2001 Apr; 25(3):573-90. PubMed ID: 11370998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
    Seeman P; Tallerico T
    Mol Psychiatry; 1998 Mar; 3(2):123-34. PubMed ID: 9577836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
    Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining dopamine D3 receptor occupancy by antipsychotic drugs via [3H]7-OH-DPAT ex vivo autoradiography and its cross-validation via c-fos immunohistochemistry in the rat brain.
    Davoodi N; te Riele P; Langlois X
    Eur J Pharmacol; 2014 Oct; 740():669-75. PubMed ID: 24967534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.